1998-2005 (n = 19) |
2006-2012 (n = 34) |
TOTAL (N = 53) |
P | |
DEMOGRAPHICS AND HIV | ||||
Male sex | 17 (90) | 30 (88) | 47 (89) | 1.00 |
Age yr, median (IQR) | 44 (41-48) | 48 (45-52) | 47 (44-50) | < 0.01 |
History of IDU | 13 (68) | 29 (91) | 42 (82) | 0.06 |
CDC category C | 5 (26) | 15 (48) | 20 (40) | 0.12 |
cART | 17 (90) | 28 (85) | 45 (87) | 1.00 |
CD4 + cells/”L, median (IQR) | 272 (110-396) | 357 (236-614) | 326 (185-535) | 0.12 |
HIV-RNA < LLOQ | 9 (47) | 26 (79) | 35 (67) | 0.02 |
Alcohol > 50 g/d | 2 (10) | 10 (29) | 12 (23) | 0.17 |
LIVER DISEASE | ||||
Hepatitis coinfection | 19 (100) | 34 (100) | 53 (100) | 1.00 |
HCV | 15 | 26 | 41 | |
HBV | 3 | 3 | 6 | |
HCV and HBV | 1 | 5 | 6 | |
Liver cirrhosis | 19 (100) | 32 (94) | 51 (95) | 1.00 |
Child-Pugh stage B/C | 11 (58) | 20 (61) | 31 (60) | 0.53 |
Liver decompensation | 10 (53) | 16 (49) | 26 (50) | 0.50 |
MELD score, median (IQR) | 12 (9-18) | 10 (8-13) | 11 (8-15) | 0.02 |
Peg-IFN/RBV therapy | 6 (32) | 15 (47) | 21 (41) | 0.22 |
CHARACTERISTICS OF HCC | ||||
Solitary tumor | 6 (32) | 14 (41) | 20 (38) | 0.40 |
Lesion diameter > 5 cm | 12 (67) | 15 (44) | 27 (52) | 0.12 |
Portal vein invasion | 7 (37) | 12 (35) | 19 (36) | 0.57 |
Metastasis | 4 (21) | 4 (12) | 8 (15) | 0.43 |
BCLC stages C or D | 13 (68) | 16 (47) | 29 (55) | 0.11 |
AFP >200 ng/mL | 9 (47) | 11 (33) | 20 (38) | 0.23 |
DIAGNOSIS OF HCC | ||||
During surveillance | 8 (42) | 14 (41) | 22 (41) | 0.60 |
Biopsy confirmation | 7 (37) | 5 (15) | 13 (24) | 0.09 |
TREATMENT OF HCC | ||||
Treated after diagnosis | 8 (42) | 24 (71) | 32 (60) | 0.04 |
Potentially curative treatment | 4 (21) | 13 (38) | 17 (32) | 1.00 |
RFA/PEI | 4 (8) | 12 (22) | 16 (30) | |
Surgical resection | 1 (2) | 3 (6) | 4 (8) | |
Liver transplantation | 1 (2) | 0 | 1 (2) | |
Noncurative treatment | 4 (21) | 12 (35) | 16 (30) | 0.42 |
TACE | 6 (11) | 9 (17) | 15 (28) | |
Sorafenib | 1 (2) | 5 (9) | 6 (11) |